In its first-quarter earnings release, BioMarin said it expects net product revenue from Kuvan of $40 million to $70 million in 2008. The brokerage also lowered its price target on the stock by $5 to $37. BioMarin’s shares recovered most of their …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BMRN at https://www.zacks.com/ap/BMRN
BioMarin Pharmaceutical gapped up sharply Thursday and posted gains in early trade. The stock pared its gains slightly before settling into a range and closed up by 7.35 at $88.16 on the highest volume of the year. BioMarin rose to a 1 …
San Rafael-based BioMarin suffered a significant financial setback this week when the Federal Drug Administration declined to approve drisapersen, the company's new drug to treat a rare muscle ... decision broke, but the stock
If you want a Stock Review on CLSN, SRPT, BMRN or CTRV then come over to http://dailystocktracker.com/register/ …
BioMarin said Monday that it will pay $17.75 for each share of the drug developer, not counting the milestone …
Under the terms of the stock purchase agreement, BioMarin paid $10 million upfront for 100 percent of Zacharon's share capital and may make potential additional payments for clinical, regulatory and commercial milestones. BioMarin
Others, such as BioMarin and Bluebird Bio ... listing its shares on Nasdaq under …
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …